New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.
Heparin and low molecular weight heparins have limitations in their efficacy and safety for the prevention and treatment of venous thromboembolism (VTE). New synthetic antithrombotic drugs, designed with the intention of improving the therapeutic window for prophylaxis and treatment, are in various stages of development. Synthetic pentasaccharides include fondaparinux and its long-acting analogue idraparinux. Dabigatran is a direct thrombin inhibitor that has undergone clinical trials for VTE prophylaxis and treatment. Direct factor Xa inhibitors include rivaroxiban, which has shown promising results for VTE prophylaxis and is being studied for VTE treatment, as well as apixaban and betrixaban, which are at earlier stages of clinical validation. These newer agents may represent viable options for prophylaxis and therapy as further clinical studies are performed.
Division of Pulmonary and Critical Care Medicine, University of California, San Diego Medical Center, 200 West Arbor Drive, San Diego, CA 92103-8378, USA. t1morris@ucsd.edu
Timothy A
TA
Morris
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides / Q000008:administration & dosage / Q000627:therapeutic use; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D000069604:Dabigatran; D000077425:Fondaparinux; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage / Q000627:therapeutic use; D009844:Oligosaccharides / Q000008:administration & dosage / Q000627:therapeutic use; D011134:Polysaccharides / Q000008:administration & dosage / Q000627:therapeutic use; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use; D011728:Pyridones / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use; D054556:Venous Thromboembolism / Q000188:drug therapy*; D015091:beta-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D000925:Anticoagulants; D001549:Benzamides; D001562:Benzimidazoles; D009025:Morpholines; D009844:Oligosaccharides; D011134:Polysaccharides; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; C479958:idraparinux; C543086:betrixaban; D000069552:Rivaroxaban; D000069604:Dabigatran; D000077425:Fondaparinux